Imugene picks exclusive manufacturer for HER-Vaxx
Imugene (ASX:IMU) has appointed Switzerland’s Mymetics to be the exclusive manufacturer for cancer immunotherapy HER-Vaxx.
Mymetics specialises in the manufacturing and formulation of virosomes, including influenza-based virosomes - which are the key delivery component of peptide-based immunotherapy HER-Vaxx.
Imugene Executive Director Dr Nick Ede commented that the partnership will be synergistic for both companies.
“Mymetics uses the same vaccine delivery platform for infectious diseases that we are using for our immuno-oncology program,” He said. “Together both companies will work to exploit the potential value of influenza-based virosomes.”
The agreement comes two months after Imugene selected another Swiss company - Bachem - to manufacture the peptide component of the treatment.
Original HER-Vaxx developer Biolife Science had previously contracted Pevion Biotech to manufacture the treatment for clinical trials. Imugene acquired Biolife Science last year in an all-stock deal.
HER-Vaxx is designed to stimulate a polyclonal antibody response to the HER-2/neu biomarker, the same target as popular anticancer drug Herceptin. The product has been through phase I trials in breast cancer and Imugene is preparing to conduct a phase II study in gastric cancer.
Imugene (ASX:IMU) shares were trading 7.14% higher at $0.015 as of around 2 pm on Wednesday.
AI-designed DNA switches flip genes on and off
The work creates the opportunity to turn the expression of a gene up or down in just one tissue...
Drug delays tumour growth in models of children's liver cancer
A new drug has been shown to delay the growth of tumours and improve survival in hepatoblastoma,...
Ancient DNA rewrites the stories of those preserved at Pompeii
Researchers have used ancient DNA to challenge long-held assumptions about the inhabitants of...
